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AbstrAct 
As childhood cancer treatment has become more effective, survival rates have improved, and 
a number of complications have been described while many of these patients reach adulthood. 
Obesity is a well-recognized late effect, and its metabolic effects may lead to cardiovascular 
disease. Currently, studies concerning overweight have focused on acute lymphocytic leuke-
mia and brain tumors, since they are at risk for hypothalamic-pituitary axis damage secon-
dary to cancer therapies (cranial irradiation, chemotherapy, and brain surgery) or to primary 
tumor location. Obesity and cancer have metabolic syndrome features in common. Thus, it 
remains controversial if overweight is a cause or consequence of cancer, and to date additional 
mechanisms involving adipose tissue and hypothalamic derangements have been considered, 
comprising premature adiposity rebound, hyperinsulinemia, leptin regulation, and the role of 
peroxisome proliferator-activated receptor γ. Overall, further research is still necessary to bet-
ter understand the relationship between adipogenesis and hypothalamic control deregulation 
following cancer therapy.  Arq Bras Endocrinol Metab. 2009;53(2):190-200.
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resumo 
Os avanços do tratamento contra o câncer infantil têm resultado no aumento da sobrevida e 
das complicações, à medida que os pacientes atingem a maioridade. A obesidade é um evento 
reconhecido, e seus efeitos metabólicos levam à doença cardiovascular. Atualmente, o estudo 
da obesidade tem enfocado a leucemia linfocítica aguda e os tumores cerebrais, já que ambos 
têm risco para lesões hipotalâmicas, secundárias às terapias (irradiação cranial, quimioterapia, 
e cirurgia) ou à localização do tumor. Obesidade e câncer têm em comum fatores para síndro-
me metabólica. Entretanto, a relação de causa e efeito entre obesidade e câncer permanece 
controversa, sendo que são considerados outros mecanismos envolvendo o tecido adiposo e 
lesões hipotalâmicas, como o rebote precoce de adiposidade, hiperinsulinemia, regulação da 
leptina, e o papel do receptor ativado por proliferadores de peroxissoma γ. Concluindo, mais 
estudos são necessários para entender a relação entre adipogênese e descontrole hipotalâmico 
em sobreviventes de câncer. Arq Bras Endocrinol Metab. 2009;53(2):190-200.
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In the last twenty years, as treatment became more ef-fective in curing children with cancer, survival rates 
have improved greatly, and while many of these patients 
reach adulthood, a significant number of long-term com-
plications (late effects with long-term medical implica-
tions) have been described. Obesity is a well-recognized 
late effect, and there is currently considerable concern 
about the metabolic/endocrine effects leading to im-
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portant implications for long-term survivors, as acceler-
ated weight gain is associated with increased morbidity 
and mortality, particularly due to cardiovascular disease 
(CVD). Moreover, social, psychological, and economic 
consequences also require attention (1).
The new paradigm for defining successful cancer 
therapy is the balance between drug efficacy and tox-
icity/late effects. Survivors of some pediatric cancer 
groups, particularly acute lymphocytic leukemia (ALL), 
brain tumors, sarcomas, lymphomas, disseminated tes-
ticular cancer, neuroblastomas, Wilms tumor, and fol-
lowing bone marrow transplantation (BMT), are rec-
ognized to present clinical features of the metabolic 
syndrome (MetS), and therefore increased risk factors 
for CVD, such as visceral obesity, insulin resistance 
(IR), glucose intolerance, dyslipidemia, arterial hyper-
tension, and endothelial dysfunction (1-9).
Currently, research on overweight/obesity in child-
hood cancer survivors has focused mostly on survivors 
of ALL or brain tumors, which have become impor-
tant disease models giving us clues for a better under-
standing of the metabolic disturbances, and some of 
the mechanisms of weight gain among cancer survi-
vors. This population is considered at particular risk 
since cranial radiation therapy (RT), surgery, or the 
tumor itself can damage the hypothalamic-pituitary 
axis. Direct damage to the satiety center in the ventro-
medial nucleus of the hypothalamus, leptin insensitiv-
ity, growth hormone (GH) deficiency, chemotherapy 
(CT), including glucocorticoids and alkylant drugs, 
and psychosocial problems, have all been pointed out 
as additional mechanisms implicated in the pathogene-
sis of obesity (10-20).
The aim of this review is to discuss the main pedi-
atric groups at risk for developing obesity after a suc-
cessful cancer treatment, the predisposing factors, and 
the most accepted mechanisms related to weight gain 
in this particular population. 
obesity AnD its role in cAncer 
Obesity is a multifactorial disorder influenced by ge-
netic, behavioral, environmental, and cultural factors. 
Recently, studies have showed that obesity in adult life 
is heralded at birth, and factors such as birth weight, 
adiposity rebound, socioeconomic status, early matu-
ration, genetic predisposition, sex, and ethnicity/race 
may have a significant effect on the propensity to de-
velop obesity from childhood to adulthood (21,22). 
Cancer and chronic diseases could possibly be con-
nected through a variety of risk factors for metabolic 
disease that both conditions may have in common, 
such as visceral obesity, hyperinsulinemia, and IR. In 
addition, the association between visceral obesity, type 
2 diabetes mellitus (T2DM), and cancer, incite specula-
tions about the mechanisms linking adiposity and IR, 
and resulting in the occurrence of certain types of can-
cer. Visceral obesity has been recognized as a risk factor 
for the development of the so-called “obesity-related 
cancers”, encompassing breast (post-menopausal), en-
dometrial, colorectal, and pancreatic carcinomas, as well 
as for other malignancies, such as leukemia, multiple 
myeloma, and non-Hodgkin’s lymphoma (20,23).
Nevertheless, mechanisms underlying the associa-
tion between adiposity and cancer still remain unex-
plained, and are only starting to be understood. On the 
other hand, it is highly controversial if carcinogenesis 
itself could possibly contribute to the development of 
obesity and MetS as well, in survivors of various ma-
lignancies. Carcinogenesis is multifactorial and depends 
not only on metabolic disturbances but also on the in-
herited genetic background (20,23,24).
Thus far, insulin-growth factor (IGF)-1 secretion 
has been associated with patterns of childhood growth, 
as well as adult stature and adiposity, suggesting that 
IGFs may contribute to a number of anthropometric 
associations with cancer risk (25). Recently, some mo-
lecular mechanisms by which insulin (closely related to 
IGF) and its tyrosine kynase receptors (closely related 
to IGF-1 receptors) play a role in cancer biology have 
been elucidated. Insulin receptors are over-expressed 
in several human malignancies and in conjunction with 
IGF-1 receptors may contribute to the formation of 
hybrid receptors. Consequently, by binding to these 
receptors, insulin stimulates specific signaling path-
ways related to IGF-1. So far, all these receptors, insu-
lin, IGF-1, and hybrid receptors, are the major targets 
for novel anticancer therapies. Additionally, specific 
polymorphisms in certain genes encoding proteins in-
volved in the IGF signaling pathway, including IGF-1 
itself, are associated with a variation in cancer risk 
(20,23,24,26-28). 
Overall, along with the neoplastic disease itself that 
probably causes changes on inflammatory mediators, 
and adipokines (leptin and adiponectin), as well as inter-
feres with insulin sensitivity and lipid metabolism, con-
siderable metabolic derangements may be aggravated 
by anticancer therapies, including CT and RT (20,26).
Adiposity and cancer
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From ADipogenesis to oncogenesis
Adipogenesis
Adipocytes originate from multipotential mesenchymal 
stem cells derived from the adipose tissue stroma. Adi-
pogenesis can be divided into two phases: determina-
tion, which results in the conversion of the stem cell into 
a preadipocyte and terminal differentiation, in which a 
preadipocyte takes on the characteristics of the mature 
adipocytes and acquires the machinery that is necessary 
for lipid transport and synthesis, insulin sensitivity, and 
the secretion of the adipocyte-specific proteins. None-
theless, it has been difficult to characterize the factors 
that lead pluripotential cells to preadipocytes, and thus 
to mature adipocyte lineage, or to describe distinct cel-
lular intermediates. It is likely that paracrine signals re-
leased from fat cells trigger the initiation of preadipo-
cyte differentiation into mature fat cells (29).
Adipocyte differentiation involves a temporarily regu-
lated set of gene expressed events, which require a cru-
cial nuclear transcription factor, the so-called peroxisome 
proliferator-activated receptor γ (PPARγ), also responsible 
for the maintenance of the adipocyte phenotype. Further-
more, adipocyte differentiation is also influenced by the 
balance of different signals, pro and anti-differentiation, 
which are provided by locally produced growth factors, 
cytokines, and circulating hormones, and can also exert an 
important influence upon adipocytes. Insulin and IGF-1 
stimulate, directly or indirectly, proliferation of preadi-
pocytes and increase expression of PPARγ. In addition, 
glucocorticoids also stimulate other transcription factors 
that play a role in adipocyte differentiation. Therefore, 
chronic excess of glucocorticoid produces increased body 
fat. On the other hand, GH stimulates preadipocyte dif-
ferentiation to mature adipocytes and limits fat storage 
(29,30). After ALL and brain tumor therapy, many sur-
vivors may develop GH deficiency, which will be further 
discussed in another section (Figure 1).
Moreover, adipocytes express the enzyme 11β-
hydroxysteroid dehydrogenase type 1, which catalyses 
the reduction of the inactive steroid (cortisone) into 
the active hormone cortisol. The expression of this en-
zyme is upregulated in differentiated adipocytes and is 
increased in visceral fat compared with subcutaneous 
Figure 1. The role of PPARγ in adipocyte differentiation and activation. 
PPARγ activation by biological or synthetic ligands alters insulin sensitivity by regulating adipokine production (increased adiponectin, and decreased TNF-α and resistin levels), 
as well as lipid storage (FFA accumulation and increased tryglicerides). This process results in decreased FFA flux to systemic circulation, as well as reduced lipid accumulation, 
and increased fat acid oxidation by liver and muscles, contributing to the state of enhanced insulin sensitivity (Adapted from reference 30). 
Adipokines
Differentiation
FFA
↑ Tryglicerids storage
PPAR γ
activation
↑ Fat acid oxidation
↓ Lipid accumulation
PPARγ
GH, IGF-1, insulin
Glucocorticoid
↑ Adiponectin
↓ TNF-α
↓ Resistin
↓ MCP-1
Adipocyte
Liver & muscles
Preadipocyte
PPARγ = peroxisome proliferator-activated receptor γ; GH = growth hormone; IGF-1 = insulin-like growth factor-1; FFA = fat free acids; TNF-α = tumor necrosis factor-alpha; MCP-1 = monocyte 
chemoattractant protein-1.
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fat, which may contribute to the preferential deposition 
of fat viscerally, rather than subcutaneously, in states of 
cortisol excess (29). This could possibly explain the al-
tered body fat composition, and distribution as well, 
during and after ALL treatment, which comprises high 
doses of glucocorticoids, particularly during the first 4 
weeks of therapy.
peroxisome proliferator-activated receptor γ (ppArγ): 
“master” regulator of adipogenesis
The adipocyte acts as an endocrine organ. Adipose tissue 
is controlled by several signals, including PPARγ, which 
belongs to the family of nuclear hormone receptors, and 
is the dominant or “master” regulator of adipogenesis. 
In response to these signals, mature adipocytes secrete 
inflammatory mediators and adipokines, which control 
endothelial function, atherogenesis, energy balance, 
and also activate intracellular pathways, regulating the 
subacute inflammatory state associated with obesity, 
and the development of IR and T2DM. Adipokines and 
inflammatory mediators comprise leptin, adiponectin, 
resistin, visfatin, estrogen, interleukins, angiotensino-
gen, lipoprotein lipase, 11β-hydroxysteroid dehydro-
genase type 1, monocyte chemoattractant protein-1 
(MCP-1), tumor necrosis factor-alpha (TNF-α), C-re-
active protein (CPR), and plasminogen activator inhibi-
tor (PAI-1) (31). Adiponectin is an adipokine inversely 
correlated with adipose tissue and, in turn, to IR. On 
the other hand, TNF-α and resistin are directly associ-
ated with IR (30).
The identity of the natural and synthetic ligands 
for PPARγ remains unresolved, and is an area of ac-
tive investigation. Several studies have showed that 
long-chain polyunsaturated fatty acids and related 
molecules are the biological ligands for PPARγ, which 
is also the biologic receptor for the thiazolidinedione 
(TDZ) antidiabetic drugs currently in widespread use 
for the treatment of T2DM. PPARγ has a central role 
in the promotion of adipogenesis and its activation in 
the adipose tissue improves whole-body insulin sen-
sitivity through a combination of metabolic actions, 
including partitioning of lipid stores and the regula-
tion of adipokine production, comprising increase 
in adiponectin levels and decreased production of 
TNF-α and resistin. Multiple studies have showed that 
deletion of PPARγ in mature adipocytes compromises 
their viability and leads to lipodystrophy and IR (30) 
(Figure 1).
ppArγ: further than fat 
The ability of PPARγ to direct the program of adipocyte 
differentiation, characterized by a complete cessation 
of cell growth, was a stimulus to examine the capacity 
of this receptor to interfere with tumor growth. The 
concentration of PPARγ is increased in adipose cells, 
but a substantial amount is also present in certain other 
cell types, such as the colonic epithelium, and epithelial 
cells of the breast and prostate. Application of PPARγ 
ligands showing an antigrowth and/or pro-differentia-
tion response have now been reported for a huge vari-
ety of cancer cells, including those derived from colon, 
lung, ovary, breast, thyroid, and prostate cells (30).
To date, PPARγ signaling has also been implicated in 
the control of atherosclerosis, macrophage function, im-
munity, and inflammatory response, but no consensus has 
been reached regarding how PPARγ activation alters cell 
growth. Therefore, genetic studies in mice have elucidated 
that the loss of even one allele of the PPARγ gene predis-
poses to cancer. Thus, in the genetic sense, PPARγ must 
be formally considered a tumor suppressor gene (30).
PPARγ ligands have been utilized in a therapeutic 
context as a monotherapy in several advanced forms 
of human cancer, including prostate, breast, and co-
lon cancer. In addition, PPARγ agonists have recently 
been combined with a number of more classical chemo-
therapeutic agents (comprising platins). Overall, it has 
remarkable antineoplastic effects both in solid cancer 
and leukemia through inhibition of cell proliferation, 
induction of apoptosis, and terminal differentiation, as 
well as inhibiting angiogenesis (30,32). 
All the factors implicated, directly or indirectly, in adi-
pogenesis, comprising the adiposity signals (particularly 
PPARγ and insulin), adipokines, as well as the hypotha-
lamic control of the appetite, may be profoundly dam-
aged by cancer itself throughout diverse pathways, or by 
the different drugs and treatments necessary to reach the 
cure. To date, there is almost no research available con-
cerning the cellular mechanisms of adipogenesis after can-
cer treatment. Thus, the link between PPARγ, oncogene-
sis, adipogenesis, and the major role of a variety of factors 
that could possibly explain adipogenesis deregulation in 
cancer survivors still remains to be established (30).
unDerlying mechAnisms For obesity in 
peDiAtric cAncer groups
Regarding adiposity in childhood cancer survivors, two 
types of cancer are of major interest: ALL and brain 
Adiposity and cancer
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tumors. They both have in common cranial RT admin-
istration, which is one of the important factors implicat-
ed in obesity physiopathology among cancer survivors. 
Nonetheless, other mechanisms, not fully understood 
yet, have been hypothesized, so both types of cancer 
are considered diverse models for comprehending obe-
sity/overweight, as well as its resulting metabolic de-
rangements (10-20,33-39).
The more conventional and frequently used methods 
to assess the relative metabolic load or risk imposed by 
fatness in childhood cancer survivors are body mass in-
dex (BMI), skinfold thickness, electrical bioimpedence, 
and the dual energy x-ray absorptiometry (DEXA), ac-
knowledged as the gold-standard (6,11-16,40).
Currently, clinical screening tools, waist circumfer-
ence (WC) and waist to hip ratio, rather than BMI, have 
been suggested in MetS definition criteria both in pedi-
atric and adult patients, as they better evaluate changes 
in body fat distribution, predominant in childhood can-
cer survivors, in place of body composition (41,42). In 
addition, another relation, the so-called waist to height 
ratio, has been positively correlated with visceral adipose 
tissue (VAT), particularly when it is greater than 0.5, 
even in post-malignancy treated subjects (5). Thus far, 
central or abdominal adiposity is assessed using com-
puted tomography (CT) or magnetic resonance imaging 
(MRI) scans at the L4-L5 level (6,43). 
The principal mechanisms involved in weight gain in 
ALL, and in brain tumor survivors, are summarized in Ta-
ble 1, and are further discussed in the following sections.
Acute lymphocytic leuKemiA 
growth hormone deficiency: role of radiotherapy 
(and chemotherapy)
Weight gain is either a short or a long-term effect of 
ALL therapy. Weight increases and body composition 
changes during the first 4 weeks of therapy due to glu-
cocorticoid administration, encompassing prednisone 
or dexamethasone. During this phase, height decreases, 
probably as a result of a partial and transient GH insuffi-
ciency or insensitivity (16), and linear growth might be 
followed or not by catch-up growth during the main-
tenance therapy (14,16). A number of ALL survivors, 
regardless of their adequate weight gain, may become 
overweight for height, due to their relative height loss, 
which is very usual after cranial RT, especially when ad-
ministered at a young age, but that may also occur in 
CT only treated patients (14,33). GH deficiency is the 
table 1. Primary mechanisms for overweight/obesity in acute lymphocytic 
leukemia and brain tumor survivors (10-20,33-39)
Acute lymphocytic leukemia
Growth hormone deficiency/Hypothalamic damage (due to):
Cranial radiation therapy (12-24 Gy)
Chemotherapy (less frequent)
Leptin deregulation
Premature adiposity rebound
Other mechanisms: 
Familial background 
Poor dietary choices 
Increased sedentary behavior 
Reduced physical activity
Brain tumors – hypothalamic obesity
Growth hormone deficiency/Hypothalamic damage (due to):
Tumor itself
Cranial (or craniospinal) radiation therapy (> 45-51 Gy)
Radical resection
Intratumoral therapy (bleomycin and/or interferon-α) 
Chemotherapy (less frequent)
Other mechanisms:
Vagally mediated hyperinsulinemia (autonomic imbalance)
Lack of sensitivity to endogenous leptin
Reduced physical activity
most frequent endocrine dysfunction observed follow-
ing cranial RT. GH is implicated not only in growth 
regulation, but also in metabolism. GH deficiency fre-
quently induces MetS-like disorders, such as visceral 
obesity, hypertriglyceridemia, low HDL-cholesterol, 
coagulopathy, and hypertension (20).
On the other hand, accelerated weight gain, rather 
than height loss, has also been observed in ALL survi-
vors, particularly during the first two years after therapy 
withdrawal (16). However, the real role played by weight 
gain in BMI increase after cancer therapy is not well-
established, because almost all the data available from 
the Childhood Cancer Survivor Study (CCSS), the larg-
est study on cancer late effects in the U.S. population, 
as well as other studies concerning weight gain in ALL 
survivors, have focused strictly on BMI, so there are few 
data on weight or height evolution (11-16,33,34). 
Excessive weight gain during ALL treatment has 
usually been related to steroid adverse effects and dis-
turbances on appetite regulation, depending on central 
nervous system treatment, as well as less energy expendi-
ture due to physical inactivity. Nevertheless, these factors 
do not fully explain overweight in this group of patients 
and influences of corticosteroid treatment and cytosta-
tics on body composition are still uncertain (14,15). 
Adiposity and cancer
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There is a well-established association between obe-
sity and cranial RT (10). Among female survivors of ALL 
and brain tumors, especially if treated with cranial RT, 
the prevalence of obesity is increased if compared with 
the general population while survivors of other malignan-
cies are frequently underweight (15). On the basis of the 
CCSS data, ALL survivors who have received more than 
20 Gy cranial RT (frequently 24 Gy) were at increased 
risk of overweight/obesity, especially females, and those 
treated before the age of five (11,12). Furthermore, oth-
er studies not only confirmed the impact of RT on weight 
gain, but also evidenced a sexually dimorphic and dose-
dependent effect of radiation on the human brain, proving 
that sex and age are important determinants of obesity in 
ALL survivors (13). Cranial RT has also been strongly re-
lated to GH deficiency, and in turn to lower IGF-1, raised 
leptin and fasting insulin concentrations, altered body fat 
distribution (abdominal obesity), and dyslipidemia in 
both sexes, but particularly in women (4,6,40). In addi-
tion, female ALL survivors have less lean mass and VAT, 
but higher total adipose tissue (TAT) and subcutaneous 
adipose tissue (SAT) than males (6). Changes in BMI are 
usually greater in the 24 Gy irradiated group compared 
with the 18 Gy sample, confirming the dose-dependent 
effect of cranial RT (13) (Figure 2).
On the other hand, a large amount of childhood 
ALL survivors have not been treated with cranial RT, or 
received low radiation doses (between 12 and 18 Gy). 
However, some of them have developed obesity, MetS 
traits, and GH deficiency as well (44). Whether CT only 
or low-dose cranial RT is related to the development of 
obesity is controversial and a matter of discussion. Nev-
ertheless, it has been greatly reported by various previ-
ous statements (14,16,35). In these studies CT com-
posed mainly by glucocorticoid was shown to decrease 
fat oxidation during fasting and to produce a significant 
increase in weight gain right after the beginning of the 
therapy and at the end of it (45). Thus far, while CT it-
self predisposes to obesity and features of MetS in ALL 
survivors, once in combination with cranial RT this ef-
fect may be intensified (1,3,4,6,8,40,46).
Nonetheless, in substantial disagreement with previ-
ous studies (11-15), a variety of statements (18,36,45) 
did not find an increase in obesity/overweight in ALL 
survivors, in spite of cranial RT administration. The first 
study developed by our group (Sao Paulo, Brazil) found 
that weight and BMI transversally determined 3.4 years 
after ALL therapy withdrawal at a mean age of 11.5 years 
did not differ between irradiated compared with nonir-
radiated subjects, only one irradiated subject (24 Gy) pre-
sented with BMI standard deviation score (SDS) > 2.0, 
and BMI SDS was similarly distributed according to the 
presence of cranial RT (18). Another study from Brasilia, 
Brazil, described a group of irradiated childhood ALL 
survivors (18-24 Gy) at a mean age of 14 years, who did 
not develop obesity at a mean 8 years after the end of CT. 
The authors justified this by explaining that patients came 
from lower economic classes of the Brazilian community, 
in which the diet is low-fat, and family overprotection of 
the sick child was probably poor (45). In addition, Nathan 
and colleagues also presented the results of a study of Ca-
nadian children and adolescent survivors of cancer (ALL, 
lymphomas, sarcomas, brain tumors, and others) in which 
the prevalence of overweight was not greater compared 
to the general population, but a substantial proportion of 
these pediatric patients were overweight, especially male 
survivors, which contrasts with the CCSS data (11), de-
spite the presence of cranial RT (18 or 24 Gy) (36). All 
these studies supported that body weight also depends on 
the interaction between genetic background, sex, ethnic-
ity/race, and environmental factors (18,36,45).
leptin regulation: sex dimorphism and genetic 
susceptibility through polymorphism 
Leptin, a hormone encoded by the ob gene and secret-
ed mainly by adipocytes, regulates appetite and energy 
expenditure by acting in the hypothalamus (18,47). 
Figure 2. Interaction between individual host characteristics and cancer therapy in 
determining overweight/obesity in childhood cancer survivors (Data from references 
11 and 37).
Chemotherapy
AGE
SEX
GENETICS
Leptin
Polymorphism
Radiotherapy Surgery
Tumor
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Moreover, it is also known to play a role in leukemia 
physiopathology as its receptors, which are members 
of the cytokine receptor super family are expressed in 
leukemia blast cells (18,48). Along with cranial RT and 
young age, genetic susceptibility through population 
leptin receptor polymorphism may contribute to BMI, 
and also influence obesity in female survivors of child-
hood ALL (37) (Figure 2).
Leptin regulation disorder and leptin resistance have 
been hypothesized to play a role in the development of 
obesity in ALL survivors. In addition, leptin itself is an 
important adiposity index during and after ALL thera-
py as it correlates significantly and positively with BMI 
(16-19), but not with age or dose of cranial RT or with 
markers of GH secretion (17,18). Previous studies com-
paring nonirradiated ALL patients with those treated 
with cranial RT (12-24 Gy) have found either similar 
levels (16, 18) or even higher leptin concentrations in 
the irradiated group (6,19,49). The pathophysiological 
significance of the hyperleptinaemia remains to be es-
tablished, but it has occurred either as a consequence 
of radiation induced hypothalamic damage or GH de-
ficiency (17-19). In addition to this, premature CVD 
has also been correlated with hyperleptinaemia and GH 
deficiency induced by cranial RT or CT only (1,3,44). 
Sex shows an important influence upon leptin levels 
and upon the relationship between BMI and leptin as 
well. Females tend to exhibit higher levels compared to 
males. Sexual dimorphism in leptin concentrations may 
be influenced by body fat distribution, therefore leptin 
correlates better with BMI and total body fat in females 
(50). However, strongest and positive correlation be-
tween leptin and BMI has been recently described by 
our group in males, even though there was no signifi-
cant difference in leptin concentrations or BMI between 
sexes. Nonetheless, body fat distribution has not been 
evaluated in this study, so that the real influence of gen-
der upon leptin, and consequently its role in body fat 
distribution, has not been clarified yet (18).
Leptin was considered an excellent nutritional 
marker and increased in ALL patients one year after CT 
withdrawal, independent of the presence of cranial RT. 
Along with the leptin increment, ALL patients tended 
to become obese (16). On the contrary, a current state-
ment described by our group showed that nonirradi-
ated ALL survivors tended to exhibit decreased leptin 
concentrations according to years elapsed since therapy 
withdrawal, but in irradiated ALL subjects serum leptin 
levels did not change as a function of time (18). 
premature adiposity rebound
The timing of adiposity rebound (AR) in childhood 
has been shown to have strong correlations with adult 
obesity. The AR is the period of childhood (typically 
between 5 and 7 years) when BMI and other indexes 
of adiposity begin to increase after reaching their nadir 
(35). Children with an earlier adiposity rebound were 
heavier and had above average BMIs. Early rebound 
is the result of higher rates of weight gain, measured 
in percentage terms, rather than slower than average 
accrual of stature. Low birth weight, and early rapid 
infancy growth is correlated with subsequent obesity 
risk in childhood and later life (51). 
The so-called premature AR is an additional mecha-
nism that might contribute to obesity in survivors of 
ALL (35), and a similar situation is observed in small-
for-gestational-age children (52), and congenital hypo-
thyroidism subjects (53), who present drastic changes 
in body composition that have been suspected to favor 
the later development of the long-term metabolic com-
plications by promoting central adiposity and IR dur-
ing early childhood (51). 
Considering that ALL occurs most often in preschool 
children aged between 3 and 5 years (and that physi-
ological adiposity rebound would only occur between 5 
and 7 years), there is an evident early rebound in these 
children, since CT administration comprising high doses 
of glucocorticoid, especially in the first 4 weeks of treat-
ment, and cranial RT, may alter body fat composition 
and distribution still during treatment, as well as in the 
following years after therapy withdrawal (6,16,40).  
other factors 
Other possible contributing mechanisms to the de-
velopment of overweight/obesity after ALL therapy 
are, as follows: familial background (38), poor dietary 
choices, increased sedentary behavior, and reduced 
physical activity (36).
brAin tumors: A moDel For hypothAlAmic 
obesity
Children with brain tumors are at an extremely high 
risk for the development of obesity after therapy, espe-
cially those with craniopharyngioma or following radi-
cal resection or cranial/craniospinal RT (medulloblas-
tomas, astrocitomas, ependymomas, and nasopharynx 
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carcinomas). Craniopharyngioma is the most common 
tumor of the hypothalamus-hyphophyseal region in 
childhood. To date, the tumor itself, and the possible 
approach including radical resection, intratumoral ther-
apy (bleomycin or interferon-α), and less frequently 
cranial RT, may result in severe neurological and en-
docrine sequelae. Craniopharyngioma surgery may also 
increase the risk of MetS still in childhood, including 
IR due to excess weight gain and GH deficiency (54-
56). Additionally, brain tumors receiving RT exceeding 
45 Gy showed an altered body composition (2). 
Brain tumor survivors with hypothalamic damage 
present a form of obesity termed “hypothalamic”, with 
a weight gain often intractable, secondary to the tumor 
itself or to cancer therapy, not responsive to diet and ex-
ercise interventions, and commonly associated with oth-
er hormonal deficiencies (particularly GH deficiency). 
A very elegant retrospective analysis was performed by 
Lustig and colleagues in an attempt to identify, among 
children diagnosed and treated for primary brain tumor, 
the more important risk factors for obesity. Patients with 
spinal cord involvement or spinal cord RT were exclud-
ed from the study (due to the possibility of height loss), 
as well as patients receiving supraphysiologic doses of 
glucocorticoids. Rates of BMI increment were system-
atically evaluated and compared with that of the gen-
eral American pediatric population, taking into account 
BMI curves. BMI change rates of brain tumor patients 
when compared with normal children were significantly 
different. No effect of ventriculoperitoneal shunting, 
steroid use or CT was noted (55). To date, the major 
risk factors that predict the development of obesity in 
brain tumor survivors were, as follows: hypothalamic 
location, extent of surgery, hypothalamic RT exceeding 
51 Gy, and the presence of hypothalamic-pituitary defi-
ciencies, particularly GH deficiency (55,56). 
The existing statements concerning uncontrolled 
hyperphagia and hypothalamic obesity secondary to 
craniopharyngioma involve patients treated with either 
surgery or RT, and correlate findings to GH deficiency 
due to hypothalamic damage (54). Experimental stud-
ies have showed the relationship between hyperphagia, 
hyperinsulinism, and weight gain with lesions of the 
ventromedial hypothalamus (VMH). Afferent vagal 
and hormonal (ghrelin, insulin, and leptin) signals are 
generated from the liver, gut, pancreas, and adipose 
tissue. These signals are interpreted in the VMH, and 
efferent signals from this area in turn stimulate either 
the sympathetic nervous system to expend energy by 
activating β-adrenergic receptors and enhance lipolysis 
(by adipocytes), heat and physical activity; or the para-
sympathetic nervous system (vagus nerve) to increase 
insulin secretion, with resultant adipogenesis and en-
ergy storage. When a lesion of the VMH occurs (due to 
the tumor itself, radical resection, intratumoral therapy 
or high-dose cranial RT), it results in dysregulation of 
pancreatic β-cell vagally mediated insulin release (au-
tonomic imbalance), leading to insulin hypersecretion, 
weight gain, and consequent IR. Different reports have 
showed that this phenomenon can be suppressed by 
pancreatic vagotomy, as well as reverted by octreotide 
administration, which prevent insulin hypersecretion 
(57) (Figure 3). Similarly described in ALL survivors, 
additional mechanisms implicated in weight gain in 
brain tumor survivors are, as follows: lack of sensitivity 
to endogenous leptin (due to hypothalamic damage), 
and physical inactivity (39,58).
other cAncer groups
In addition to ALL and brain tumors, particularly cran-
iopharyngiomas and those receiving high-dose cranial 
RT, other types of pediatric tumors have also been as-
sociated with the occurrence of obesity (particularly vis-
ceral obesity), as well as other features of the MetS, as 
follows: sarcomas, lymphomas, disseminated testicular 
cancer, neuroblastomas, Wilms tumor, and following 
BMT (1-9). In the following lines, we will concentrate 
on sarcomas and BMT. 
So far, male visceral abdominal obesity, and an in-
creased prevalence of MetS traits, comprising hyperten-
sion, and hypertriglyceridemia, has been described in 
pediatric sarcoma survivors (predominantly Ewings), 
treated with multi-agent CT, with or without RT. 
However, no association between GH deficiency and 
the occurrence of MetS traits was observed. Physical 
inactivity due to altered ambulatory function, a conse-
quence of surgical resection and/or RT to trunk, pelvic 
and lower extremity may also contribute for the devel-
opment of obesity in pediatric sarcoma survivors (9).
Currently, it is becoming clear from a number of 
studies among adult and pediatric recipients of BMT 
that they are also at risk of developing abdominal adi-
posity, IR and other features of MetS, such as impaired 
glucose tolerance, T2DM, dyslipidemia, and hyper-
tension (5,7,59,60). Total body irradiation (TBI), 
untreated hypogonadism, and abdominal adiposity (a 
known feature of GH deficiency) were considered risk 
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VENTROMEDIAL
HYPOTHALAMUS
Pancreas
Liver & Gut
Sympathetic nervous system
Vagus nerve
Adipocyte
Figure 3. Schematic representation of the interaction between the ventromedial hypothalamus (VMH) and peripheral signals leading to vagally mediated hyperinsulinemia in 
brain tumor survivors (hypothalamic obesity). 
Afferent vagal and hormonal signals are generated from the liver, gut, pancreas, and adipocytes, and are interpreted in the VMH. Efferent signals from the VMH in turn stimulate 
either the adipocytes through sympathetic nervous system to enhance lipolysis or the vagus nerve to increase insulin secretion, with resultant adipogenesis. When there is a 
lesion of the VMH, it results in dysregulation of pancreatic β-cell vagally mediated insulin release, leading to insulin hypersecretion, weight gain, and consequent IR (Adapted 
from reference 57).
Leptin
Insulin
Ghrelin
factors for the development of hyperinsulinemia, im-
paired glucose tolerance, and T2DM in pubertal and 
adult survivors, having TBI the strongest association 
(5). Nonetheless, the mechanisms underlying this still 
remain unclear, and to date the effect of TBI on the 
function of adipose tissue in secreting adipokines has 
not been studied yet (5,60).
conclusion remArKs AnD Future issues
The prevalence and pathogenesis of obesity, particu-
larly visceral adiposity, and MetS in long-term survivors 
of cancer, their significance, as well as the relationship 
between these factors and the development of CVD af-
ter cancer treatment have yet to be clarified. Weight 
gain, especially in some specific cancer groups predis-
posing to MetS traits, must encourage a more active 
lifestyle during the first years of therapy, particularly in 
ALL and brain tumor individuals. 
Rapid weight gain in infancy may be a risk factor for 
later adiposity. Early infancy may provide an opportuni-
ty for interventions aimed at reducing later obesity risk. 
Additionally, research should focus on understanding 
the underlying biologic and physiological basis of sex-
specific and genetic-determined risks (polymorphisms). 
Current nutritional strategies that promote catch-up 
growth should include some monitoring of adiposity. 
Hypothalamic obesity often results in devastating 
metabolic and psychosocial complications, requiring 
provision of dietary and behavioral modifications, en-
couragement of regular physical activity, psychological 
counseling, as well as antiobesity drugs.
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Further research is still necessary to define the epi-
demiology, risk factors, and mechanisms behind the 
development of overweight and metabolic disorders in 
survivors of pediatric cancers. Longitudinal prospective 
studies are still necessary to estimate actual prevalence 
and facilitate the unravelling of the underlying mecha-
nisms in change of body distribution rather than com-
position, and the relationship between adiposity and 
hormonal regulation. Recommendations for future 
research also include exploring ways to assess visceral 
adiposity, to identify better biochemical markers for 
prediction of disease progression, including PPARγ, 
and insulin, and to effectively prevent visceral obesity as 
a MetS trait in youth.
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